Metastatic gallbladder adenocarcinoma with signet-ring cells: A case report

Abstract

IntroductionSignet-ring cell carcinoma is a rare and aggressive variant of mucinous adenocarcinoma. Only a few cases of gallbladder adenocarcinoma with signet-ring cells have been reported and because of this there is a lack of knowledge about the behavior and biology of this pathology.Case presentationWe present the case of a 63-year-old Arab man with gallbladder signet-ring cell adenocarcinoma. He had an elective cholecystectomy and refused chemotherapy. Two months later, a small hepatic metastatic nodule was found, and nine months later he presented with multiple metastases in the liver, lymphatic nodes, both pleuras, peritoneum and subcutaneous tissue.ConclusionThe proliferation of signet-ring cells in a gallbladder adenocarcinoma worsens the prognosis of an already adverse neoplasm. New lines of treatment in chemotherapy, such as cisplatin, or new biological therapy, such as monoclonal antibody c-myc oncogene, should be encouraged to improve the survival and life quality of these oncologic patients.

Extreme Rare Case of Primary Signet Ring Cell Carcinoma of Gall Bladder-Case Report

“…Gallbladder carcinoma is the fifth most common malignant neoplasm of the digestive tract, adenocarcinoma being the most frequent histological type (Misra et al, 2003;Donohue et al, 1998;Bazan et al, 2011). Gallbladder carcinoma is more common in females than males and its incidence shows the tendency to increase with age (Donohue et al, 1998;Pesic et al, 2002).…”

“…Signet ring cell carcinoma (SRCC) can arise from virtually any organ but most are from the stomach, breast, and colon (Bazan et al, 2011;Van Breda Vriesman et al, 2007). Regardless of the tissue origin, SRCCs frequently metastasize to peritoneal surfaces, regional lymphnodes, ovaries and lungs (Chu & Weiss, 2004;Karabulut, Yildirim, Abaci, Ilgici, & Ozyilkan, 2008;Panić, Marusić, & Mijić, 2010).…”

“…Most tumors (90%) are adenocarcinomas and the relative survival rate is low (14.5% at 5%) (Misra S., Charturvedi, Misra, N. C., & Sharma, 2003;Donohue, Stewart, & Menck, 1998;Bazan et al, 2011). More frequent in females than males (3 to 4:1), over 90% of the patients are 50 years of age or older (Donohue et al, 1998;Pesic, Karanikolic, Djordjevic, Gmijovic, & Basic, 2002).…”

Carcinoma vesicular de células en anillo de sello: diseminación poco frecuente: Reporte de un caso con tomografía computada por emisión de positrones con fluor 18-deoxiglucosa

“…El 75% de los pacientes se diagnostican en fases avanzadas. No existe un tratamiento quimioterápico protocolizado y efectivo, lo que justifica la elevada mortalidad 3 , siendo lo más utilizado gemcitabina en monodroga o asociada a platinos 7 .…”

“…El carcinoma de células en anillo de sello (CCAS) vesicular, es una variante agresiva 2 , de mal pronóstico e infrecuente del adenocarcinoma mucinoso 3 . Chile es uno de los países con mayor incidencia de cáncer de vesícula biliar (CVB) a nivel mundial 4 .…”